Loading...
•
Jun 30, 2020
ACADIA Q2 2020 Earnings Report
Reported a net sales increase of 32% for NUPLAZID compared to Q2 2019 and updated NUPLAZID net sales guidance for 2020.
Key Takeaways
ACADIA Pharmaceuticals reported a net sales of $110.1 million for NUPLAZID in Q2 2020, a 32% increase compared to Q2 2019. The company updated its NUPLAZID net sales guidance for 2020 to $430 to $450 million.
NUPLAZID net sales were $110.1 million, a 32% increase over Q2 2019.
FDA filed the supplemental NDA for pimavanserin for dementia-related psychosis with a PDUFA action date of April 3, 2021.
ADVANCE-2, a Phase 3 study evaluating pimavanserin for negative symptoms of schizophrenia, was initiated.
GAAP R&D and SG&A guidance were decreased, and year-end cash, cash equivalents, and investment securities are expected to be $570 to $590 million.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.com Forward Guidance
ACADIA provided financial guidance for 2020, including NUPLAZID net sales, GAAP R&D and SG&A expenses, non-cash stock-based compensation expense, and year-end cash, cash equivalents, and investment securities.
Positive Outlook
- NUPLAZID net sales guidance is updated to $430 to $450 million.
- GAAP R&D guidance is decreased to $265 to $280 million.
- GAAP SG&A guidance is decreased to $400 to $420 million.
- Non-cash stock-based compensation expense guidance of $90 to $100 million is unchanged.
- 2020 year-end cash, cash equivalents, and investment securities is expected to be $570 to $590 million.